Two for the price of two: Cubist fronts $1.24b for Trius, Optimer

Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.

Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.

Cubist agreed to pay Trius investors $13.50 per share for a total of $707 million and offered Optimer stockholders $10.75...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas